FDA Acceptance of QSYMIA Supplemental Application by VIVUS LLC
The FDA has accepted a supplemental application for QSYMIA, a combination of phentermine and topiramate, submitted by VIVUS LLC.
Asset / Drug
Drug and asset intelligence for QSYMIA with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
Combination Therapy
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.